Results: 888 patients with RA with 3,396 follow-up visits were included in the study. 13,636 daily air pollution records were retrieved. We found an exposure-response relationship between the concentration of air pollutants and the risk of having abnormal CRP levels (Figure 1). Patients exposed to greater concentrations of air pollutants were at higher risk of having CRP levels ≥ 5 mg/L. Patients exposed to PM10 concentrations ≥ 50 $\mu\text{g}/\text{m}^3$ had a 70% higher risk of having CRP levels ≥ 5 mg/L (OR 1.696 95% CI, 1.245-2.311). Among RA patients, 440 patients (49.5%) had at least 2 follow-up visits with a difference in DAS28-CRP of more than 1.2 points (with current DAS28-CRP ≥ 3.2), serving as our sample for the case-crossover study. Concentrations of CO, NO, NO₂, NO_x, PM10, PM2.5 and O₃ were higher in the 60-day period preceding a flare (Table 1). Sensitivity analyses considering geometric mean and cumulative concentrations yielded similar results (data not shown). Remarkably, we found that the cumulative exposure to NO₂ in the 60 days preceding a flare was approximately 500 $\mu\text{g}/\text{m}^3$ higher than the low disease activity visit, an exposure that equates to approximately 200 passively smoked cigarettes (3.5 cigarettes per day on a 60-day period).

Figure 1. Odds of having abnormal CRP serum levels (≥ 5 mg/L) at different exposures of PM10 and PM2.5 (mean concentration in the 60 days before assessment)

Table 1. Case-crossover study. Mean concentrations (mean and Area Under the Curve) of air pollutants in the 60 days before low-disease activity visit and flare visit (DAS28-CRP difference >1.2)

Pollutant		Control period (low disease activity, n=440)	Hazard period (flare, n=440)	p value
CO $\mu\text{g}/\text{m}^3$	Mean	0.38	0.42	0.001
	AUC	22.00	24.53	0.001
NO $\mu\text{g}/\text{m}^3$	Mean	19.23	24.11	0.002
	AUC	1,120.53	1,403.88	0.002
NO ₂ $\mu\text{g}/\text{m}^3$	Mean	30.91	32.44	0.042
	AUC	1,800.96	1,892.05	0.040
NO _x $\mu\text{g}/\text{m}^3$	Mean	60.34	69.35	0.004
	AUC	3,515.77	4,041.06	0.004
PM10 $\mu\text{g}/\text{m}^3$	Mean	31.21	33.65	0.011
	AUC	1,789.22	1,942.52	0.005
O ₃ $\mu\text{g}/\text{m}^3$	Mean	31.08	33.79	0.002
	AUC	1,776.37	1,934.35	0.001
PM2.5 $\mu\text{g}/\text{m}^3$	Mean	23.08	24.74	0.018
	AUC	1,272.61	1,403.60	<0.001

Conclusion: We found a striking association between air pollution and RA disease severity and reactivations in a cohort of patients followed over a 5-year period. The exposure to high levels of air pollutants was associated with increased CRP levels and a higher risk of experiencing a flare of arthritis. This excessive risk was evident at very low levels of exposure, even below the proposed threshold for the protection of human health. Our study has important and direct consequences. In order to reduce the burden of RA, public and environmental health policy makers should aim to diminish gaseous and PM emissions to a larger extent as currently recommended.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.216

OP0179

DISCONTINUATION RATE OF TOFACITINIB IS SIMILAR WHEN COMPARED TO TNF INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS: POOLED DATA FROM TWO RHEUMATOID ARTHRITIS REGISTRIES IN CANADA

M. Movahedi¹, D. Choquette², L. Coupal², A. Cesta¹, X. Li¹, E. Keystone³, C. Bombardier¹ on behalf of OBRI and RHUMADATA Investigators. ¹UHN, Toronto General Hospital Research Institute, Toronto, Canada; ²Institut de Rhumatologie de Montréal, RHUMADATA, Montreal, Canada; ³University of Toronto, Medicine, Toronto, Canada

Background: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-modifying

antirheumatic drugs (bDMARDs), including tumor necrosis factor inhibitors (TNFi). The similarity in retention of TNFi and TOFA was previously reported separately by the Ontario Best Practices Research Initiative (OBRI) and the Quebec cohort RHUMADATA[®].

Objectives: To increase the study power, we propose to evaluate the discontinuation rate (due to any reason) of TNFi compared to TOFA, using pooled data from both these registries.

Methods: RA patients enrolled in the OBRI and RHUMADATA initiating their TOFA or TNFi between 1st June 2014 (TOFA approval date in Canada) and 31st Dec 2019 were included. Time to discontinuation was assessed using adjusted Kaplan-Meier (KM) survival and Cox regression models. To deal with confounding by indication, we estimated propensity scores for covariates with a standard difference greater than 0.1. Models were then adjusted using stratification and inverse probability of treatment weight (IPTW) methods. Multiple imputation (Imputation by Chained Equation method, N=20) was used to deal with missing data for covariates at treatment initiation.

Results: A total of 1318 patients initiated TNFi (n=825) or TOFA (n=493) with mean (SD) disease duration of 8.9 (9.3) and 13.0 (10.1) years, respectively. In the TNFi group, 78.8% were female and mean age (SD) at treatment initiation was 57.6 (12.6) years. In the TOFA group, 84.6% were female and mean (SD) age at treatment initiation was 59.5 (11.5) years. The TNFi group was less likely to have prior biologic use (33.9%) than the TOFA group (66.9%). At treatment initiation, the mean (SD) CD4I was significantly ($p<0.05$) lower in the TNFi group [20.0 (11.7)] compared to the TOFA group [22.1 (12.4)]. Physical function measured by HAQ-DI was also significantly lower ($p<0.05$) in the TNFi compared to the TOFA group (1.2 vs. 1.3).

Over a mean follow-up of 23.2 months, discontinuation was reported in 309 (37.5%) and 182 (36.9%) of all TNFi and TOFA patients, respectively. After adjusting for propensity score deciles across 20 imputed datasets, there was no significant difference in discontinuation between treatment groups (adjusted HRs: 0.96, 95% CI: 0.78-1.18; $p=0.69$). The results were similar for two propensity adjustment methods. Figure 1 shows IPTW adjusted KM survival curves comparing discontinuation rates in patients treated with TNFi and TOFA.

Figure 1. Note: Propensity Score Weighted (IPTW) Survival Curves was performed using one imputed dataset

Conclusion: In this pooled real-world data study, we found that TNFi and TOFA retention is similar in patients with RA. In the next step we will analysis the data for specific reasons of discontinuation. We will also repeat analysis comparing discontinuation in the first users versus those after one or more biologic failure.

Disclosure of Interests: Mohammad Movahedi: None declared, Denis Choquette Grant/research support from: Rhumadata[®] is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada., Louis Coupal: None declared, Angela Cesta: None declared, Xiuying Li: None declared, Edward Keystone Grant/research support from: Amgen, Merck, Pfizer Pharmaceuticals, PuraPharm. Speaker Honoraria Agreements: AbbVie, Amgen, Bristol-Myers Squibb Company, Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi-Genzyme, Samsung Bioepis. Consulting Agreements/Advisory Board Membership: AbbVie, Amgen, Bristol-Myers Squibb Company, Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi-Genzyme, Samsung Bioepis, Claire Bombardier Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted

grants from: Abbvie, Amgen, Aurora, Bristol-Myers Squibb, Celgene, Hospira, Janssen, Lilly, Medexus, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB. Dr. Bombardier held a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology
DOI: 10.1136/annrheumdis-2021-eular.912

OP0180

IMPACT OF RF AND ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS ON 2-YEAR RETENTION OF ABATACEPT IN PATIENTS WITH RA

R. Alten¹, X. Mariette², R. M. Flipo³, R. Caporali^{4,5}, M. H. Buch^{6,7}, Y. Patel⁸, R. Sanmarti⁹, S. Marsal¹⁰, M. T. Nurmohamed¹¹, H. Griffiths¹², P. Peichi¹³, B. Bannert¹⁴, A. Forster¹⁵, M. Chartier¹⁶, S. Connolly¹⁷, Y. Elbez¹⁸, C. Rauch¹⁹, V. Khaychuk²⁰, K. Lozenski²¹. ¹Schlosspark-Klinik University, Department of Internal Medicine, Rheumatology, Berlin, Germany; ²Université Paris-Saclay, AP-HP, Hôpital Bicêtre, Department of Rheumatology, Paris, France; ³Centre Hospitalier Universitaire de France, Department of Rheumatology, Lille, France; ⁴University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; ⁵G. Pini Hospital, Clinical Rheumatology Unit, Milan, Italy; ⁶University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; ⁷University of Manchester, Division of Musculoskeletal & Dermatological Sciences, Manchester, United Kingdom; ⁸Hull Royal Infirmary, Rheumatology, Hull, United Kingdom; ⁹Hospital Clinic de Barcelona, Rheumatology Department, Barcelona, Spain; ¹⁰Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain; ¹¹ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands; ¹²University Hospital Geelong, Barwon Rheumatology Service, Geelong, Australia; ¹³Evangelical Hospital, Department of Internal Medicine, Vienna, Austria; ¹⁴Universitätsspital Basel, Rheumatologische Universitätsklinik, Basel, Switzerland; ¹⁵Schulthess Klinik, Department of Rheumatology, Zürich, Switzerland; ¹⁶Bristol Myers Squibb, Non-Registralional Data Generation, Rueil-Malmaison, France; ¹⁷Bristol Myers Squibb, Global Drug Development, Princeton, United States of America; ¹⁸Deepcover, Biostatistics, Puteaux, France; ¹⁹Bristol Myers Squibb, Medical Immunology & Fibrosis, Munich, Germany; ²⁰Bristol Myers Squibb, US Medical Immunology and Fibrosis, Princeton, United States of America; ²¹Bristol Myers Squibb, Immunology and Fibrosis, Princeton, United States of America

Background: Up to 50% of patients with RA discontinue DMARD treatment within 18 months.¹ However, up to 20% of patients who fail multiple treatments may have a good treatment response to another therapy.¹ Predictive biomarkers, such as RF and anti-citrullinated protein antibodies (ACPAs), may be useful to stratify patients with RA to the most appropriate treatment.¹ ASCORE (Abatacept SubCutaneous in Routine Clinical Practice; NCT02090556) was a 2-year, observational, prospective, multicentre study of SC abatacept for the treatment of RA in routine clinical practice.² **Objectives:** To determine if RF/ACPA serostatus and treatment line impact abatacept retention in patients with RA in a *post hoc* analysis of ASCORE.

Methods: Eligible patients, aged ≥ 18 years, with active moderate-to-severe RA (ACR/EULAR 2010 criteria) who were IV abatacept-naïve and initiated SC abatacept 125mg once weekly, were enrolled into two cohorts: biologic (b) DMARD-naïve patients and those with ≥ 1 prior bDMARD treatment failure. This *post hoc* analysis assessed abatacept retention rate at 2 years in a subset of patients with RF/ACPA serostatus data (n=1748) from the ASCORE study (N=2892; as observed). Baseline (BL) serostatus groups examined by treatment line were: RF/ACPA double positive (+/+) RA, RF/ACPA single positive (RF+/ACPA- or RF-/ACPA+) RA (data not shown) and RF/ACPA double negative (-/-) RA. Last observation carried forward (LOCF) analyses were used to assess change from BL and measures of disease remission (DAS28 [CRP] < 2.6 , CDAI ≤ 2.8 , and SDAI ≤ 3.3) in patients with +/- RA versus -/- RA. **Results:** BL demographic and disease characteristics were similar across serostatus groups and treatment lines (Table 1). Mean age was 57.1 and 57.8 years for +/- RA and -/- RA, respectively. Mean DAS28 (CRP) was 4.7 and 4.8 for +/- RA and -/- RA, respectively. In patients with +/- RA, abatacept retention was greater when given as first-line treatment (57% vs 48% when given as $\geq$ second-line) (Figure 1). Retention was similar in patients with -/- RA regardless of treatment line. After 2 years, mean (SE) change from BL (LOCF) in DAS28 (CRP) was -1.41 (0.06) and -0.97 (0.09) for patients with +/- and -/- RA, respectively. For patients with +/- RA, mean (SE) change from BL in DAS28 (CRP) was -1.62 (0.08) for those in whom abatacept was first-line and -1.19 (0.08) for those in

whom abatacept was $\geq$ second-line. For patients with -/- RA, mean (SE) change from BL in DAS28 (CRP) was -1.03 (0.13) for those in whom abatacept was first-line and -0.93 (0.12) for those in whom abatacept was $\geq$ second-line. Remission rates (LOCF) were significantly ($p < 0.0001$) higher in patients with +/- RA vs -/- RA respectively: DAS28 (CRP) 38.4% (n=393) versus 19.3% (n=62); CDAI 50.6% (n=513) versus 33.0% (n=107); and SDAI 49.5% (n=497) versus 32.5% (n=102). **Conclusion:** In this real-world analysis, patients with +/- RA treated with first-line abatacept had higher retention than patients receiving abatacept as a $\geq$ second-line therapy. Remission rates on abatacept were higher in patients with +/- RA versus -/- RA. These results support early treatment with abatacept and highlight the importance of further evaluating precision medicine approaches in RA.

REFERENCES:

- Smolen JS, et al. *Ann Rheum Dis* 2020;79:685–699.
- Alten R, et al. *Ann Rheum Dis* 2019;78(suppl 2):A1639.

Figure 1. Retention rates by treatment group in patients with +/- RA

Acknowledgements: Professional medical writing and editorial assistance was provided by Lindsay Craik at Caudex and was funded by Bristol Myers Squibb. This study was funded by Bristol Myers Squibb.

Disclosure of Interests: Rieke Alten Speakers bureau: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Lilly, Pfizer, Consultant of: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Lilly, Pfizer, Grant/research support from: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Lilly, Pfizer, Xavier Mariette Consultant of: Bristol Myers Squibb, Galapagos, Gilead, GlaxoSmithKline, Janssen, Pfizer, UCB, Rene-Marc Flipo Speakers bureau: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche-Chugai, Grant/research support from: Amgen, Janssen, Novartis, Pfizer, Roberto Caporali Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Galapagos, Gilead, Lilly, Merck Sharp & Dohme, Pfizer, Roche, Samsung Bioepis, Sanofi, UCB, Consultant of: Galapagos, Gilead, Janssen, Lilly, Merck Sharp & Dohme, Maya H Buch Speakers bureau: AbbVie, Consultant of: AbbVie, Eli Lilly, Gilead, Merck Serono, Pfizer, Roche, Sanofi, Grant/research support from: Gilead, Pfizer, Roche, UCB, Yusuf Patel: None declared, Raimón Sanmartí Speakers bureau: AbbVie, Bristol Myers Squibb, Gebro, Janssen, Lilly, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, Consultant of: AbbVie, Bristol Myers Squibb, Gebro, Lilly, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, Grant/research support from: Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, Sara Marsal Speakers bureau: Bristol Myers Squibb, Celgene, Pfizer, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol Myers Squibb, Celgene, Galapagos, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, UCB, Grant/research support from: AbbVie, Bristol Myers Squibb, Celgene, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, UCB, M.T. Nurmohamed Speakers bureau: AbbVie, Bristol Myers Squibb, Eli Lilly, Roche, Sanofi, Consultant of: AbbVie, Celgene, Celltrion, Eli Lilly, Janssen, Grant/research support from: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp & Dohme, Mundipharma, Novartis, Pfizer, Roche, Sanofi, Hedley Griffiths Consultant of: AbbVie, Gilead, Janssen, Novartis, Peter Peichi: None declared, Bettina Bannert: None declared, Adrian Forster: None declared, Melanie Chartier Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Sean Connolly Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Yedid Elbez Consultant of: Bristol Myers Squibb, Christiane Rauch Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Vadim Khaychuk Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Karissa Lozenski Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb

DOI: 10.1136/annrheumdis-2021-eular.932

Table 1. BL demographics and disease characteristics by RF/ACPA status

	+/- RA (n=1079)		-/- RA (n=343)	
	First-line (n=511)	$\geq$ second-line (n=568)	First-line (n=140)	$\geq$ second-line (n=203)
Age	57.1 (13.4)	57.1 (12.2)	59.5 (14.7)	56.6 (13.2)
DAS28 (CRP)	4.7 (1.2)	4.7 (1.2)	4.8 (1.1)	4.8 (1.2)
CDAI	26.6 (12.5)	26.6 (12.4)	27.7 (12.5)	28.6 (13.8)
SDAI	28.1 (13.1)	28.1 (12.9)	29.1 (12.9)	30.2 (14.7)

Data are mean (SD). Patients with missing data for BL RF/ACPA status are excluded. ACPA=anti-citrullinated protein antibody; BL=baseline.